Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase

BACKGROUND & OBJECTIVES: Imatinib is the standard first-line treatment for chronic myeloid leukaemia (CML) patients. About 20 to 30 per cent patients develop resistance to imatinib and fail imatinib treatment. One of the mechanisms proposed is varying expression levels of the drug transporters....

Descripción completa

Detalles Bibliográficos
Autores principales: Malhotra, Hemant, Sharma, Pratibha, Malhotra, Bharti, Bhargava, Shipra, Jasuja, Sandeep, Kumar, Madhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613438/
https://www.ncbi.nlm.nih.gov/pubmed/26354214
http://dx.doi.org/10.4103/0971-5916.164250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613438/
https://www.ncbi.nlm.nih.gov/pubmed/26354214
http://dx.doi.org/10.4103/0971-5916.164250

Ejemplares similares